Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dextromethorphan + guaifenesin
- Development stage
- Approved
- Lead developer
- Strides Pharma Science
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dextromethorphan + guaifenesin is a combination pharmaceutical developed by Strides Pharma Science. It is a small molecule drug administered orally, primarily indicated for the relief of cough and chest congestion. Dextromethorphan acts as an NMDA receptor antagonist and a Sigma-1 receptor agonist, providing antitussive (cough suppressant) effects. Guaifenesin functions as an expectorant, helping to thin and loosen mucus in the airways, making it easier to clear from the chest.
- Brand names
- Mucinex DMAlka-Seltzer Plus Maximum StrengthChildren Giltuss Cough and Chest CongestionChildren's Delsym Cough+Chest Congest DMChildren's Robitussin Cough and ChestChildren's Robitussin Cough and Chest Congestion DMRobitussin CFActinel CoughActinel Pediatric CoughBroncotron DColdmist DMDespec DMDonatussin DMExeClear-DMGenexpect PELiquicough DMPanMist DMPseudo CoughRelacon DMRelacon DM NRRelasin DMRu-Tuss-DMTL-Dex DMTri Vent DMTri-Vent DMTRISPEC PSETusnel Pediatric CoughZ-Cof DMZ-Cof DMX
- Other names
- dextromethorphan + guaifenesin
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)SERT (Sodium-dependent serotonin transporter)SIGMAR1 (Sigma non-opioid intracellular receptor 1)
Beyond the preview
Go deeper on dextromethorphan + guaifenesin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dextromethorphan + guaifenesin.